furosemide norameda
norameda, uab - furozemidas - injekcinis ar infuzinis tirpalas - 10 mg/ml - furosemide
aminoplasmal hepa 10%
b.braun melsungen ag - izoleucinas/leucinas/lizino acetatas/metioninas/fenilalaninas/treoninas/triptofanas/valinas/argininas/histidinas/glicinas/alaninas/prolinas/asparto rūgštis/asparaginas monohidratas/acetilcisteinas/glutamo rūgštis/ornitino hidrochloridas/serinas/acetiltirozinas - infuzinis tirpalas - 8,8 g/13,6 g/10,6 g/1,2 g/1,6 g/4,6 g/1,5 g/10,6 g/8,8 g/4,7 g/6,3 g/8,3 g/7,1 g/2,5 g/0,55 g/0,8 g/5,7 g/1,66 g/3,7 g/0,86 g/1000 ml; 8,8 g/13,6 g/10,6 g/1,2 g/1,6 g/4,6 g/1,5 g/10,6 g/8,8 g/4,7 g/6,3 g/8,3 g/7,1 g/2,5 g/0,55 g/0,8 g/5,7 g/1,66 g/3,7 g/0,86 g/10 - amino acids
hartil hct
egis pharmaceuticals plc - ramiprilis/hidrochlorotiazidas - tabletės - 2,5 mg/12,5 mg; 5 mg/25 mg - ramipril and diuretics
vidaza
bristol-myers squibb pharma eeig - azacitidinas - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antinavikiniai vaistai - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
supplin
sandoz gmbh - metronidazolas - plėvele dengtos tabletės - 500 mg - metronidazole
azacitidine celgene
celgene europe bv - azacitidinas - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antinavikiniai vaistai - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
azacitidine betapharm
betapharm arzneimittel gmbh - azacitidinas - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antinavikiniai vaistai - azacitidine betapharm fluorouracilu gydyti suaugusiems pacientams, kurie negali gauti kraujodaros kamieninių ląstelių transplantacijos (hsct) su:tarpinės-2 ir didelės rizikos mielodisplazinio sindromai (vni) pagal tarptautinių prognostinė balų sistemą (ipss),lėtinis myelomonocytic leukemija (cmml) su 10 % iki 29 % čiulpuose blastų be myeloproliferative sutrikimas,ūminės mieloidinės leukemijos (ppp) su 20 % iki 30 % blastų ir multi-lineage dysplasia, pagal pasaulio sveikatos organizacijos (pso) klasifikacija,aml su > 30 % čiulpuose blastų pagal pso klasifikaciją.
azacitidine mylan
mylan ireland limited - azacitidinas - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antinavikiniai vaistai - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
azacitidine auxilia
auxilia pharma oÜ - azacitidinas - milteliai injekcinei suspensijai - 25 mg/ml - azacitidine
trimazin 30 %, peroraliniai milteliai
kela laboratoria n.v. (belgija) - peroraliniai milteliai - sulfadiazine (as sodium sulfadiazine) - 250.0 mg; trimethoprim - 50.0 mg; excipients up to 1.0 g - veršeliams ir kiaulėms, sergantiems infekcinėmis ligomis, kurių sukėlėjai jautrūs sulfadiazinui ir trimetoprimui, gydyti ir profilaktiškai.